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There is uncertainty about the magnitude of the effect of screening mammography on breast cancer mortality. The relevance
and validity of evidence from dated randomized controlled trials has been questioned, whereas observational studies often
lack a valid comparison group. There is no estimate of the effect of one screening invitation only. We exploited the geographic
rollout of the Dutch screening mammography program across municipalities to estimate the effects of one additional biennial
screening invitation on breast cancer and all-cause mortality. Population administrative data provided vital status and cause of
death of a cohort of women aged 49–63 in 1995 over 17 years. Linear probability models were used to estimate the mortality
effects. We estimated 154 fewer breast cancer deaths (95% conﬁdence interval: 40–267; p = 0.01) over 17 years in a
population of 100,000 women aged 49–63 who received one additional biennial screening invitation, which corresponds to an
9.6% risk reduction for a woman of age 56. The estimated effect on all-cause mortality was negative but not close to statistical
signiﬁcance. Our study shows that one single invitation for breast cancer screening is effective in reducing breast cancer
mortality, which is important for health policy. The effect is smaller than previous estimates of the effect of invitation for
multiple screens, which further emphasizes the importance of achieving regular participation.
Introduction
It is 35 years since randomized controlled trials (RCTs) appeared
to show that mammography screening reduced breast cancer
mortality by 25%,1,2 and yet there remains debate about the pres-
ently achievable magnitude of effect.3–9 Weaknesses in the meth-
odology of several RCTs,4 their limited relevance today given
advances in treatment, and their inability to establish effective-
ness of population-based screening programs have led to greater
reliance on observational studies.5 The validity of evidence from
such studies10–16 may also be doubted when a comparison group
is lacking or inappropriate, the follow-up period is limited, or
potential confounders are not adequately controlled. Comparison
of national trends before and after the introduction of organized
screening is certainly biased by changes in background risk,
increased awareness of breast cancer, and improved effectiveness
of treatment.12 Comparison of before-and-after trends in a group
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that gains access to screening with trends observed over a differ-
ent period in a group not covered by screening13,14 does not elim-
inate the effect of these confounders.
Exploiting Dutch population and cancer registries with 100%
coverage rate and detailed data on the date the screening mam-
mography program started in eachmunicipality, our study avoided
these limitations by comparing breast cancer mortality across two
groups of women of the same age observed over the same 17-year
period who got access to the program at different dates due to its
staggered rollout. The group that entered the program earlier had
received one more invitation for screening in every year of our
follow-up period. Provided breast cancer mortality would not oth-
erwise have differed systematically across the two groups of munic-
ipalities, any observed difference in mortality can be attributed to
the additional biennial screening invitation. Contrary to most eval-
uations of screening mammography, we use a cohort analysis
which is better suited to distinguishing a screening invitation effect
from confounding factors than designs that do not follow the same
cohort over time. To our knowledge, this is the ﬁrst article to iden-
tify the effect of one (additional) screen invitation.
Methods
Screening program
In 1989, the Netherlands initiated a population-based, orga-
nized screening program for women aged 50 to 69. This was
rolled out by municipality following no particular pattern over
9 years. By 1997, almost 800,000 women were targeted and
80% accepted an invitation for screening.17 In 1998, the upper
age limit was extended to 75. Within 3 years, this extension
was implemented nationwide.18
All eligible women in a zipcode area simultaneously receive a
biennial personalized invitation to get screened in a (mostly)
mobile unit at a speciﬁc date and time. There is no charge. Mam-
mograms are independently assessed by two radiologists, and a
woman is recalled if both agree on a positive result. Clinical
assessment and breast cancer treatment is universally available
without charge.
Data and study population
We used municipality and death registers accessed via Statistics
Netherlands to identify date of birth, vital status, date and cause
of death, and zipcode for every female resident of the Nether-
lands from January 1995 to December 2011. From the Dutch
Cancer Registry, we retrieved municipality-level breast cancer
incidence for 1989–1994 and 5-year breast cancer prevalence as
of January 1994. The month in which the screening program
started to operate in each municipality (between January 1989
and December 1997) was provided by the National Evaluation
Team for Breast Cancer Screening.11 As the registers are not
linked at the individual level before 1995, and so vital status, as
well as date and cause of death, are not available before that
year, we avoid selective survival bias by restricting the analysis
to 138 (out of 484) municipalities where the program began in
January 1995 or later (Supporting Information Fig. S1).
We selected women aged 49–63 on January 1, 1995. Those
aged 49 were included, because a woman becomes eligible for
screening in the year she turns 50. Those older than 63 were
excluded because the number of screening invitations they
received due to the extension of the program to women aged
up to 75 varied (Supporting Information Fig. S2), and we
could not observe this variation because we did not know the
municipality-speciﬁc launch dates of the extension.
For each woman aged 49–63 on January 1, 1995, we identiﬁed
(from municipality of residence) the month and year she was
ﬁrst invited for screening, whether she was alive at December
31, 2011, and, if not, the cause of death.
Statistical analyses
The study design is valid if the program rollout was uncorrelated
with prerollout breast cancer mortality risk at the municipality
level. To check the plausibility of this assumption, we regressed
program entry date on indicators of pre-1995 breast cancer mor-
tality risk, which include municipality-speciﬁc demographics, as
well as breast cancer incidence and prevalence. We include both
pre-1995 incidence and prevalence, because the change in the
prevalence rate is equal to the incidence rate less the mortality
rate.19 Hence, conditional on incidence prior to 1995, pre-1995
prevalence varies only with the number of breast cancer deaths
and so controls for municipality-level variation in breast cancer
mortality prior to 1995.
We estimated the intention-to-treat effect of delayed (from
early 1995) initial invitation for screening on breast cancer
mortality risk. We created a binary indicator equal to 1 if the
woman had died of breast cancer (i.e., primary cause regis-
tered as International Classiﬁcation of Diseases [ICD]-9 code
174 or ICD-10 code 50) by December 31, 2011, and 0 if she
was alive or had died from any other cause. A linear probabil-
ity model was used to estimate the effect on the probability of
What’s new?
To date, there is still uncertainty about the magnitude of the effect of screening mammography on breast cancer mortality.
Here, the authors exploited the geographic rollout of the Dutch screening mammography program and high-quality national
population, cancer, and death registries to avoid limitations of observational research by comparing breast cancer mortality
across groups of women of the same age who joined the mammography program at different dates. The analysis provides a
unique estimate of the effect of one additional invitation for screening mammography on breast cancer mortality (around 10%)
and delivers evidence in favour of the effectiveness of such screening.
2 One additional screening mammography on mortality
Int. J. Cancer: 00, 00–00 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
C
an
ce
r
T
he
ra
py
an
d
P
re
ve
n
ti
on
death from breast cancer, and the estimated regression coefﬁ-
cients were multiplied by 100,000 to show the impact on the
number of deaths over the 17-year period per 100,000 women
initially aged 49–63.
In a ﬁrst model, we used all municipalities that entered the
program in 1995–1997 and regressed the mortality indicator on
a series of binary variables that identiﬁed the 6-month interval
during which the program started to operate in the municipality
in which each woman was resident at the start of 1995. This esti-
mates the intention-to-treat effect of delayed initial screening
invitation on breast cancer mortality risk. However, it does not
isolate the effect of the receipt of one additional screening invita-
tion over the entire period during which a woman is eligible for
the program. Compared to women ﬁrst invited in 1995, those
invited in 1996 have received the same number of screening invi-
tations in even-numbered calendar years (1998, 2000, etc.) and
one more in odd-numbered years (1999, 2001, etc.). For this rea-
son, we estimate a second model in which we discard municipal-
ities that entered the program in 1996 and regressed the
mortality indicator on a single binary variable that distinguished
access to the program in 1997 from entry in 1995. In every year
throughout our follow-up period, women ﬁrst invited in 1995
have received exactly one more screening invitation than women
ﬁrst invited in 1997, and so comparison of these groups identiﬁes
the effect of an additional invitation.
We used the second, more parsimonious speciﬁcation to
conduct sensitivity and validity analyses. Model speciﬁcation
was based on the “post-double-selection” method.20 We con-
sidered municipality-speciﬁc demographics, as well as breast
cancer incidence and prevalence, as potential controls, but in
the models used to obtain the estimates presented, we only con-
trolled for those variables that were signiﬁcantly correlated either
with breast cancer mortality from 1995 to 2011 or with the date
screening started during this period (Supporting Information
Table S3 conﬁrms robustness to othermodel speciﬁcation choices).
All models controlled for age in January 1995 in years (49 reference
category, binary variables for 50 and 51 to 63).
Sensitivity and validity analyses included controlling for
province ﬁxed effects, restricting to women who did not move
between municipalities, replicating the analysis on women
aged 72–77 in January 1995, controlling for initial screening
uptake, and estimating by logistic rather than least squares
regression.
We further estimated the effect of one additional biennial
screening invitation on all-cause mortality by deﬁning a binary
indicator of death from any cause between January 1995 and
December 2011 and modeling this using the “post-double-selec-
tion” method (Supporting Information Table S6 shows estimates
from other model speciﬁcation choices).20
Standard errors were clustered over women living in the same
municipality at the time of the ﬁrst invitation. All hypotheses tests
were against a two-sided alternative, and a p value of less than
0.05 was taken to indicate statistical signiﬁcance. All computa-
tions were done using Stata® version 14.
Ethics approval, consent to participate, and data availability
This research did not have to undergo a medical ethical review
according to the Dutch Medical Research Involving Human Sub-
jects Act, because the individuals were not subjected to proce-
dures or were required to follow rules of behavior. For the same
reason, consent to participate was not required for our study.
The data that support the ﬁndings of our study derive from
three sources. The majority of the data were provided by Statistics
Netherlands via a Remote Access facility (GBAADRESBUS
1995–2011 and DO 1995–2011) and are available from Statistics
Netherlands via https://www.cbs.nl/en-gb/our-services/customis
ed-services-microdata/microdata-conducting-your-own-research
to authorized institutions on payment of a fee. These data from
Statistics Netherlands were linked to data of the Netherlands
Cancer Registry (available from the Netherlands Comprehensive
Cancer Organization via http://www.cijfersoverkanker.nl/data-
request-58.html) and to data on program implementation dates
and participation rates (available from the National Evaluation
Team for Breast Cancer Screening https://www.erasmusmc.nl/
public-health/research-education/screening-evaluation/?lang=en).
As stipulated in the data agreement, Statistics Netherlands has the
right to preview the ﬁndings of this project prior to publication to
ensure that privacy sensitive, individual-speciﬁc information is not
revealed.
Results
Rollout of the screening program
Of the 138 municipalities that entered the screening program
after 1994, 33 began screening in the ﬁrst half of 1995 and 7 did
not start screening until the second half of 1997 (Table 1). The
size of the female population per municipality (11,606, on aver-
age) did not differ signiﬁcantly across municipalities categorized
by the 6-month period in which each entered the program
(Table 1). Neither did the percentage of female inhabitants who
were age-eligible for screening (19%, on average). Prior to the
program operating in any of these municipalities, annual breast
cancer incidence, which averaged 117 per 100,000 females of all
ages in the period 1989–1994, also did not differ signiﬁcantly by
date of program entry. The 5-year breast cancer prevalence
(449 per 100,000 females in 1994, on average) did differ signiﬁ-
cantly (p = 0.03). However, multivariate analyses revealed that
date of program entry was not signiﬁcantly associated (individually
or jointly) with preprogram prevalence, incidence, size of female
population, and its share in the screening-eligible age range
(Supporting Information Tables S1 and S2 and Figs. S3 and S4). As
these factors were also uncorrelated with breast cancer mortality
between 1995 and 2011 (Supporting Information Table S3), they
were excluded from the regression used to estimate the program
impact onmortality.
Subjects
In a population of 256,712 women who in January 1995 were
aged 49–63 and resident in the 138 municipalities where screen-
ing had not yet started by that date, there were 3,604 (1.4%)
Van Ourti et al. 3
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breast cancer deaths and 38,341 (14.9%) deaths in total over the
17 years to December 2011. Mean (standard deviation [SD])
age in January 1995 was 55.6 (4.4) years. For the estimation of
the impact of one additional screening invitation, we drop all
women ﬁrst invited in 1996. This leaves us with 148,920 women
in 86 municipalities who experienced identical cumulative breast
cancer (1.4%) and all-cause mortality rates (14.9%) over the
17 years to December 2011.
Effects on breast cancer mortality
The top panel of Table 2 shows the effects of delayed access to the
screening program on cumulative breast cancermortality between
1995 and 2011. It shows (rescaled) estimates from a regression
of the binary indicator of breast cancer death on binary indicators
of the half-year interval in which each woman’s municipality
entered the program. For every 100,000 women aged 49 who lived
in municipalities where the program was implemented between
Table 2. Association between date of entry to screening program and cumulative breast cancer mortality 1995–2011
Date of program access
Number of breast cancer
deaths per 100,000 (95% CI)1
Difference in deaths per 100,000 from
number in reference (95% CI)2 p value
Effects of delayed access to the screening
program (6 month indicators; N = 256,712)3
January to June 1995 (reference) 1,138 (952 to 1,324)
July to December 1995 35 (−104 to 174) 0.62
January to June 1996 −44 (−161 to 74)) 0.46
July to December 1996 10 (−137 to 157) 0.90
January to June 1997 163 (21 to 306) 0.03
July to December 1997 186 (33 to 339) 0.02
Effect of one additional biennial screening
invitation (1997 indicator; N = 148,920)4
1995 (reference) 1,116 (901 to 1,332)
1997 154 (40 to 267) 0.009
1Scaled model constant indicating estimated mortality in the reference group aged 49 and with access to the screening program from the period indi-
cated in left-hand column.
2Scaled coefficient on indicator of period in which screening program started to operate in municipality.
3Data for women aged 49–63 in January 1995 in 138 municipalities where the screening program was implemented between January 1995 and
December 1997. Estimates are scaled coefficients from linear probability models with the dependent variable a binary indicator of having died from
breast cancer between 1995 and 2011. The models include a (series of) binary indicator(s) of the period in which the screening program started to oper-
ate in the municipality of residence and yearly indicators of age in January 1995 (49 [reference], dummies for 50, 51, to 63). Statistical inference
accounts for clustering among women in a municipality at its entry to the program.
4Data for women aged 49–63 in January 1995 in 86 municipalities where the screening program was implemented between January and December
1995 and between January and December1997. Estimates are scaled coefficients from linear probability models with the dependent variable a binary
indicator of having died from breast cancer between 1995 and 2011. The models include a (series of) binary indicator(s) of the period in which the
screening program started to operate in the municipality of residence and indicators of age in January 1995 (49 [reference], dummies for 50, 51, to 63).
Statistical inference accounts for clustering among women in a municipality at its entry to the program.
Table 1. Preprogram characteristics of municipalities by date of entry to the screening program1
Date of program entry
Number of
municipalities
(N = 138)
Female
population,
1989–19942
Percentage of
females aged 50–69,
1989–19943
Breast cancer
incidence,
1989–19944
Five-year breast
cancer prevalence,
January 19945
Percentage of females
aged 50–69 screened
at ﬁrst invitation6
January to June 1995 33 11,045  16,349 19  2 112  23 419  104 81  5
July to December 1995 34 10,887  10,785 19  3 117  25 438  100 81  3
January to June 1996 33 12,968  13,851 19  2 120  37 487  111 81  4
July to December 1996 19 13,721  17,217 20  3 130  29 480  87 80  6
January to June 1997 12 10,175  10,574 19  3 113  43 460  164 82  5
July to December 1997 7 8,044  4,601 19  4 102  29 373  115 79  6
p value7 0.95 0.47 0.31 0.03 0.89
All municipalities 138 11,606  13,645 19.0  2.0 117  30 449  111 81  5
1Plus–minus values are means  SD. Only municipalities that started organized screening between January 1995 and December 1997.
2The number of females in a municipality averaged over the period 1989–1994.
3Percentage of the female population in a municipality who is aged 50–69 and so eligible for screening, averaged over the period 1989–1994.
4Municipality-specific median over the period 1989–1994 of the annual number of newly diagnosed breast cancer cases per 100,000 female inhabitants.
5The number of cancer patients who were diagnosed with breast cancer in the 5 years preceding January 1994 and still alive at that time per 100,000
female inhabitants of a municipality.
6Data available for only 133 municipalities.
7p values are for the Kruskal-Wallis test of no difference by date of program entry.
4 One additional screening mammography on mortality
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January and June 1995, we estimated that 1,138 had died from
breast cancer by the end of 2011 (95% conﬁdence interval [CI],
952 to 1,324; p < 0.001). There was no signiﬁcant (statistically or
substantively) effect on breast cancer mortality of accessing the
program up to 18 months after those covered from the ﬁrst half of
1995. Once the delay lengthened to 2 years, the estimated effect
increased greatly in magnitude to reach a signiﬁcant 163 additional
deaths per 100,000 women over the 17 year period. Gaining access
to the program 2 years earlier is estimated to have reduced the
risk of dying from breast cancer within 17 years by 10.4% (163/
(1,138 + 163 + 266)) for women aged 56 (mean age; Supporting
Information Table S4). The point estimate of the effect increased
further, although not signiﬁcantly, when the delay reached 2.5 years.
The bottom panel of Table 2 shows the estimate of the
mortality effect of one additional biennial screening invitation by
excluding municipalities that got access to the program in 1996.
Municipalities that implemented the program in 1997 are esti-
mated to have experienced an additional 154 breast cancer deaths
per 100,000 women by the end of 2011 (95% CI, 40 to 267;
p = 0.009) compared to those that entered in 1995. For a women
aged 56 (mean age in our sample), this corresponds to a 9.6%
(154/(1,116 + 154 + 339)) reduction in the risk of breast cancer
death for those who gained access to screening in 1995 and so
received one more invitation for screening over the years they were
age-eligible for the program (Supporting Information Table S3).
Figure 1 shows how the estimated number of excess breast
cancer deaths that arose from one additional biennial screening
invitation accumulated over the follow-up period. The point esti-
mate for 1998 indicates that between 1995 and 1998, there were
30 extra deaths per 100,000 women aged 49–63 who gained
access to screening in 1997 compared to those getting access in
1995, although the estimate is insigniﬁcant. From 2004, the effect
of entry to the program in 1997 versus 1995 on the accumulated
number of deaths is consistently signiﬁcant. The number of
excess deaths increased until 2007 and then leveled off, indicating
that 10 years after the differential exposure to screening it ceased
to impact on breast cancermortality.
Sensitivity and validity checks
The analyses reported in Table 3 demonstrate robustness of
the estimates and support the validity of the study design to
estimate the effect of one additional biennial screening invita-
tion. To allow for province-level differences in breast cancer
mortality (“province ﬁxed effects”), we had to drop 50 munici-
palities in three provinces where the program had been fully
implemented by 1997. Although losing 47% of the sample of
women reduced statistical precision leading to a marginally
insigniﬁcant estimate, the estimated effect of an additional
screening invitation is contained in the 95% CI reported in
Table 2. Then, controlling for province ﬁxed effects increased
Figure 1. Effect of one additional biennial screening invitation on cumulative breast cancer mortality to different endpoints. The ﬁgure shows
the estimated effect of getting access to the screening program in 1997 rather than 1995 on the number of breast cancer deaths from
January 1995 to the end of each year indicated per 100,000 women who were aged 49–63 in January 1995. Estimates are scaled coefﬁcients
on the binary indicator of year of program entry in linear probability models with the dependent variable a binary indicator of having died
from breast cancer between January 1995 and the end of the respective year. All models include yearly indicators of age in January 1995,
that is, 49 (reference) and dummies for 50, 51, to 63. Error bars show 95% conﬁdence intervals computed allowing for clustering at the
municipality level.
Van Ourti et al. 5
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the estimate but not substantially. Restricting the sample to
women who did not move between municipalities reduced the
estimate to some degree but again not signiﬁcantly. When we
applied the study design to women aged 72–77 in January
1995 who were not eligible for screening, we found no effect.
This indicates that breast cancer mortality in this population
was unrelated to obtaining access to the program in 1995 ver-
sus 1997 and supports the assumption that background risk in
the eligible population did not vary systematically across
municipalities that entered at different times.
Analyses conducted using women in a subset of 83 municipali-
ties with requisite data conﬁrmed that the timing of program
rollout was also uncorrelated with screening uptake at the ﬁrst invi-
tation (Table 1 and Supporting Information Fig. S5 and Tables S1
and S2). Controlling for this participation rate had little impact on
the estimated effect of one additional biennial screening invitation
(Supporting Information Table S5).
The point estimate indicates that access to the program in 1997,
as opposed to 1995, raised all-cause mortality but the estimate is
very imprecise and not statistically signiﬁcant. Although we could
not establish that the geographical rollout of the program bymunic-
ipality was unrelated to all-cause mortality risk prior to 1995, we
were able to conﬁrm that rollout in 1997 was unrelated to all-cause
mortality rates in 1995 (discussion in Supporting Information).
Estimation by logistic regression rather than least squares
produced no appreciable change in the estimates (Supporting
Information Tables S1–S6).
Some additional sensitivity checks are reported in the
Supporting Information.
Discussion
Our study found that the Dutch screening mammography pro-
gram reduced breast cancer mortality. This has been shown before,
butmore importantly, this is the ﬁrst and only estimate of the effect
of one additional screening invitation in the literature. High-quality
data on screening invitation and on individual mortality available
in the Netherlands made this analysis possible. Women initially
aged 49–63 who received one more invitation for screening over
the entire time they were eligible (by age) for the program were
estimated to experience 154 fewer breast cancer deaths per 100,000
over 17 years. This is equivalent to a 9.6% reduction in the cumula-
tive risk of dying from breast cancer from one additional screening
invitation over the eligible age range. This estimate is much lower
than the 23% reduction the International Agency for Research on
Cancer estimated by averaging effects of different lengths of expo-
sure to screening.5 It is substantially smaller than an estimate of the
impact of the Dutch breast cancer screening program based on a
before-and-after study,11 but it is not at odds with the Two-County
Trial where a difference of 2.5 screens during 7 years did lead to a
27 to 31% reduction in breast cancer mortality after 29 years.21
Case-control evaluations of the Dutch program15,16 produced
larger estimates of the mortality effect, because they estimated the
impact of the screen(s) (not invitation) preceding diagnosis, which
are obviously the most effective.
Nationwide advances in breast cancer treatment do not con-
found our estimates as we follow a single cohort of women over
time. However, if there were geographical variation in quality of
breast cancer treatment that is correlated with the spread of the
program, then it could lead to bias. Our sensitivity checks and the
pattern in Figure 1 suggest that this is unlikely, but it cannot be
ruled out a priori. Sankatsing et al.22 recently focused on differ-
ences among early (1987–1992), intermediate (1993–1994), and
late screening adopting municipalities (1995–1997) and found
similar screening-attributable reductions in breast cancer mortal-
ity, suggesting that the screening (invitation) effect is not con-
founded by the increased availability of adjuvant treatment
Table 3. Effect of one additional biennial screening invitation on cumulative mortality—sensitivity and validity checks1
Check Included confounders
Effect of program access in 1997
versus 1995 on deaths
per 100,000 (95% CI) p value
Effect on breast cancer mortality, eligible women
aged 49–63 in January 1995
Control for province fixed effects (N = 69,254)2
No Age January 1995 114 (−40 to 268) 0.14
Yes Age January 1995 139 (24 to 254) 0.02
Exclude women moving out of/from
municipality in 1995–1997 (N = 143,424)
Age January 1995 126 (13 to 238) 0.03
“Placebo effect” on breast cancer mortality,
ineligible women aged 72–77 in January 1995
(N = 33,081)
Age January 1995 −101 (−544 to 342) 0.65
Effect on all-cause mortality, eligible women aged
49–63 in January 1995 (N = 148,920)3
Age January 1995; female
population size (1989–1994)
392 (−621 to 1,406) 0.44
1Estimates are scaled coefficients on binary indicator of program entry in 1997 rather than in 1995 from linear probability models with the dependent
variable a binary indicator of having died between 1995 and 2011. All regressions include age in January 1995 in years (49 [reference category],
dummies for 50, 51, to 63, except in placebo test to 72 [reference category], 73, 74, 75, 76, 77). Statistical inference accounts for clustering among
women in a municipality at its entry to the program.
2Municipalities in the three provinces where screening was already fully implemented by the beginning of 1997 are dropped.
3Female population size is the number of females in a municipality averaged over the 1989–1994 period.
6 One additional screening mammography on mortality
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between early and late adopters. This was further corroborated by
not detecting an effect on older women not eligible for screening
(Table 3 and discussion in Supporting Information), although
ﬁnding no statistically signiﬁcant effect on all-cause mortality
(Table 3) could be due to insufﬁcient power.
Our estimate may also be smaller than earlier estimates of the
impact of the Dutch breast screening program, because it was
obtained from a slightly younger population (49–63 compared
to, respectively, 55–7416,22 and 50–6911,15).
Use of administrative data covering a period of 17 years allowed
us to monitor breast cancer mortality among women who received
their ﬁrst screening invitation at different ages but who were other-
wise similar. Support for the validity of the study design was dem-
onstrated by the fact that the program rollout was not related to
preprogram breast cancer mortality risks (i.e., incidence and preva-
lence of breast cancer jointly). By making comparisons within a
single cohort of women, we avoided relying on simple time trend
analysis, comparison of different cohorts, or a combination of these
study designs. These approaches do not adequately account for
underlying trends in breast cancer mortality12,23,24 or they rely on
strong assumptions to separate the effect of breast cancer screening
access from confounding trends (discussion in Supporting
Information).11,13–16 Advances in breast cancer awareness25,26 did
not confound our estimate, because we followed a single cohort of
eligible women over time.
Our study has some limitations. One is that we have no infor-
mation on opportunistic mammography screening (and/or cancer
treatment) in the municipalities prior to the implementation of
screening. Therefore, we cannot rule out a priori that opportunis-
tic screening uptake was systematically related to the rollout of
the program, even though opportunistic screening is and was
uncommon in the Netherlands.27 Opportunistic screening and
overdiagnosis can also weaken the correlation of breast cancer
mortality with each of incidence and prevalence prior to 1995,27
but that does not invalidate using incidence and prevalence
together to control for pre-1995 breast cancer mortality as change
in prevalence equals incidence minus mortality.19 Another limita-
tion is that we had no information on advanced-stage breast can-
cer diagnoses among the women in our cohort and we cannot
conﬁrm at the same individual level that the effect we ﬁnd of one
additional screening invitation on breast cancer deaths arises pri-
marily by reducing the incidence of advanced-stage breast
cancers, which would be the most likely mechanism.27–29 Other
mechanisms sometimes claimed to explain changes in mortality
after the introduction of screening induced change in the
attribution of deaths to breast cancer30–33 and improvements in
patient management. The high degree of reliability of the Dutch
cause of death statistics,34 the positive but insigniﬁcant point esti-
mate for an effect on all-cause mortality, and the robustness of
the estimates to allowing for province-ﬁxed effects all cast some
doubt on the relevance of these potential mechanisms to the
interpretation of our results (discussion in Supporting Informa-
tion). That said, we are not able to falsify these mechanisms with
the data available. A ﬁnal limitation concerns the evolution of
breast cancer deaths among the cohort of women who got access
to the program in 1996. We exclude these women when estimat-
ing the impact of one additional biennial screening invitation
(bottom panel Table 2) because the number of invitations they
received compared to the number of invitations received by
women who were ﬁrst invited in 1995 (and in 1997) varies over
the follow-up period. Although conﬁdence in the validity of the
research design is bolstered by the robustness of the estimated
effect of an additional screening invitation to various sensitivity
checks and by the absence of any effect when the empirical strat-
egy is applied to a cohort of older women who were not exposed
to the screening program, failing to ﬁnd that breast cancer mor-
tality increases signiﬁcantly and continuously with increases in
the length of delay to program entry over the ﬁrst 2 years exam-
ined (1995–1996; top panel Table 2) does not lend further sup-
port to the effectiveness of screening. However, comparison made
between municipalities entering the program at different times in
1995 and 1996 do not separate the pure effect of delayed entry
from that of receiving an additional screen.
Conclusions
We used high-quality data to produce the ﬁrst estimate of the
effect of one additional invitation for screening mammography
on breast cancer mortality and deliver evidence in favor of the
effectiveness of such screening. We estimate that one extra invi-
tation for screening reduced breast cancer mortality by 10%.
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